Researchers built a three-layer human blood-vessel model that shows how fibroblasts amplify the vascular pathology of ...
Scribe Therapeutics is preparing to take its first cardiometabolic programme into the clinic in mid-2026, positioning STX-1150 as a potentially durable alternative to today’s chronic lipid-lowering ...
What is prime editing and what is it used for? Prime editing was described initially by the laboratory of Dr. David Liu in 2019 (1). This powerful tool combines the DNA-scanning and ...
CMN Intelligence has released the CMN Clinical Trials Q2 2026 Global Report, based on data from the CRISPR Medicine News Global Clinical Trials... A mutation-agnostic CRISPR-Cas strategy that inserts ...
Researchers built a three-layer human blood-vessel model that shows how fibroblasts amplify the vascular pathology of Hutchinson-Gilford progeria... Clinical: FDA Backs Single-Trial Pathway for ...
Researchers have used CRISPR-Cas9 to remove CD28 from donor T cells and prevent fratricide before equipping them with ...
Screening ionisable lipids with a gene-editor-sized RNA identified LC-1, an LNP component that retained potency as cargo ...
Wave Life Sciences has reached alignment with the US Food and Drug Administration on a registrational pathway for WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin ...
The first approved CRISPR medicine has now shown similarly strong results in children as young as five years old with sickle cell disease and transfusion-dependent β-thalassaemia. In a pair of phase 3 ...
A portable CRISPR-Cas13 assay detected mpox virus with 100% sensitivity and specificity in clinical samples from Sierra Leone. The SHINE test identified as few as 10 copies/µL and delivered results in ...
A hybrid CRISPR design pipeline improves the predictability of genome editing outcomes in mouse embryos. By favouring microhomology-mediated end joining (MMEJ) and validating guides in stem cells, the ...
A genome-wide CRISPR-Cas9 screen to identify transcription factor SOX2 as a critical regulator of PROM1, the gene encoding CD133, in glioblastoma stem cells. Knocking out SOX2 reduced CD133 expression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results